PPS Use in IC Patients Increases Risk for Pigmentary Maculopathy

Pentosan polysulfate sodium (PPS) use for interstitial cystitis (IC) treatment increases the risk for pigmentary maculopathy. In a study of 110,300 women, hazard ratios were 1.31 for IC without PPS use, 1.70 for IC with less than five years PPS use, and 3.10 for IC with at least five years of PPS use.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ